# Study to Assess AFM24 in Advanced Solid Cancers

> **NCT04259450** · PHASE1,PHASE2 · TERMINATED · sponsor: **Affimed GmbH** · enrollment: 85 (actual)

## Conditions studied

- Advanced Solid Tumor

## Interventions

- **DRUG:** 14 mg AFM24
- **DRUG:** 40 mg AFM24
- **DRUG:** 80 mg AFM24
- **DRUG:** 160 mg AFM24
- **DRUG:** 320 mg AFM24
- **DRUG:** 480 mg AFM24
- **DRUG:** 720 mg AFM24

## Key facts

- **NCT ID:** NCT04259450
- **Lead sponsor:** Affimed GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-04-07
- **Primary completion:** 2023-07-12
- **Final completion:** 2024-06-24
- **Target enrollment:** 85 (ACTUAL)
- **Why stopped:** Enrollment into expansion cohorts in Phase 2 part was terminated due to sponsor decision
- **Last updated:** 2025-07-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04259450

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04259450, "Study to Assess AFM24 in Advanced Solid Cancers". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04259450. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*